Treatment Results of 14 Patients with Dysphagia after Resection of Primary Brain Tumor at a Medical Facility Specializing in Rehabilitation

2021 ◽  
Vol 72 (3) ◽  
pp. 124-131
Author(s):  
Hiroyuki Ito ◽  
Takakuni Kato ◽  
Chiaki Koizumi ◽  
Yasushi Suzuki ◽  
Teiji Tanahashi ◽  
...  
Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1411
Author(s):  
Don Carlo Ramos Batara ◽  
Moon-Chang Choi ◽  
Hyeon-Uk Shin ◽  
Hyunggee Kim ◽  
Sung-Hak Kim

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor in adults, with a poor median survival of approximately 15 months after diagnosis. Despite several decades of intensive research on its cancer biology, treatment for GBM remains a challenge. Autophagy, a fundamental homeostatic mechanism, is responsible for degrading and recycling damaged or defective cellular components. It plays a paradoxical role in GBM by either promoting or suppressing tumor growth depending on the cellular context. A thorough understanding of autophagy’s pleiotropic roles is needed to develop potential therapeutic strategies for GBM. In this paper, we discussed molecular mechanisms and biphasic functions of autophagy in gliomagenesis. We also provided a summary of treatments for GBM, emphasizing the importance of autophagy as a promising molecular target for treating GBM.


2021 ◽  
Vol 22 (12) ◽  
pp. 6385
Author(s):  
Maya A. Dymova ◽  
Elena V. Kuligina ◽  
Vladimir A. Richter

Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly resistant to conventional radiation and chemotherapy, and is not amenable to effective surgical resection. The present review summarizes recent advances in our understanding of the molecular mechanisms of therapeutic resistance of GBM to already known drugs, the molecular characteristics of glioblastoma cells, and the barriers in the brain that underlie drug resistance. We also discuss the progress that has been made in the development of new targeted drugs for glioblastoma, as well as advances in drug delivery across the blood–brain barrier (BBB) and blood–brain tumor barrier (BBTB).


2010 ◽  
Vol 128 (9) ◽  
pp. 2230-2239 ◽  
Author(s):  
Taichang Jang ◽  
Joy M. Calaoagan ◽  
Eunice Kwon ◽  
Steven Samuelsson ◽  
Lawrence Recht ◽  
...  

Neurology ◽  
1994 ◽  
Vol 44 (10) ◽  
pp. 1927-1927 ◽  
Author(s):  
H. B. Newton ◽  
C. Newton ◽  
D. Pearl ◽  
T. Davidson

2021 ◽  
pp. 45-48
Author(s):  
Babul Reddy Tatireddy

Glioblastoma is an uncommon primary brain tumor accounts for upto 15.4% of all primary brain tumors. Although several modern therapies against glioma are discovered, management is still a critical concern. The existing therapies were relatively inconsistent; moreover, the procedures as well are difcult to treat. These ineffective therapeutic approaches led researchers to identify the novel biomarkers that can be implemented with the existing therapies for better management. In this view, along with biomarker research, a literature search for exosomal PTEN detection in glioblastoma was conducted and the recent studies observed that exosomes can transport tumor-suppressive proteins (PTEN) and oncogenic mRNAs, microRNAs to a recipient cell, which subsequently activates the downstream signaling pathways and inuences the cellular phenotype. These exosomes facilitate the transfer of PTEN released from tumor cells to receipt cells that leads to tumor progression. Similarly, glioma was also associated with a reduction or loss of PTEN expression. Hence, our present review aimed to provide a holistic picture of glioblastoma, its pathogenesis and novel biomarkers with an emphasis on PTEN detection in exosomes for the early identication of glioblastoma


2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Zu-Gui Li ◽  
Min-Ying Zheng ◽  
Qi Zhao ◽  
Kai Liu ◽  
Jia-Xing Du ◽  
...  

2019 ◽  
pp. 121-144 ◽  
Author(s):  
Steven S. Rosenfeld ◽  
E. Wayne Massey

Sign in / Sign up

Export Citation Format

Share Document